$WGS
GeneDx Holdings Corp. Stock $wgs

$wgs Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000181833122000046 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$53.94M	$64.20M
YoY Change	-15.98%	37.61%
Cost Of Revenue	$48.32M	$68.52M
YoY Change	-29.49%	84.51%
Gross Profit	$5.625M	-$4.323M
YoY Change	-230.12%	-145.42%
Gross Profit Margin	10.43%	-6.73%
Selling, General & Admin	$72.33M	$137.4M
YoY Change	-47.36%	554.37%
% of Gross Profit	1285.88%
Research & Development	$21.32M	$53.13M
YoY Change	-59.88%	305.72%
% of Gross Profit	378.93%
Depreciation & Amortization	$5.803M	$4.902M
YoY Change	18.38%	104.25%
% of Gross Profit	103.16%
Operating Expenses	$93.65M	$190.5M
YoY Change	-50.85%	458.86%
Operating Profit	-$89.31M	-$196.7M
YoY Change	-54.59%	634.56%
Interest Expense	$808.0K	$723.0K
YoY Change	11.76%	-401.25%
% of Operating Profit
Other Income/Expense, Net	$12.41M	$4.882M
YoY Change	154.18%	-2339.45%
Pretax Income	-$76.90M	-$191.8M
YoY Change	-59.9%	610.54%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$76.90M	-$191.8M
YoY Change	-59.9%	610.54%
Net Earnings / Revenue	-142.56%	-298.71%
Basic Earnings Per Share	-$0.31	-$348.80
Diluted Earnings Per Share	-$0.31	-$348.80
COMMON SHARES
Basic Shares Outstanding	244.4M shares	549.8K shares
Diluted Shares Outstanding	244.4M shares	549.8K shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$315.0M	$58.65M
YoY Change	437.07%
Cash & Equivalents	$315.0M	$58.65M
Short-Term Investments
Other Short-Term Assets	$4.096M	$15.07M
YoY Change	-72.82%
Inventory	$36.32M	$32.97M
Prepaid Expenses	$17.24M	$14.93M
Receivables	$37.64M	$33.34M
Other Receivables	$125.0K	$349.0K
Total Short-Term Assets	$410.4M	$140.2M
YoY Change	192.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$99.39M	$64.63M
YoY Change	53.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.953M	$3.596M
YoY Change	93.35%
Total Long-Term Assets	$107.2M	$79.06M
YoY Change	35.66%
TOTAL ASSETS
Total Short-Term Assets	$410.4M	$140.2M
Total Long-Term Assets	$107.2M	$79.06M
Total Assets	$517.7M	$219.3M
YoY Change	136.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$68.88M	$42.10M
YoY Change	63.6%
Accrued Expenses	$2.458M
YoY Change
Deferred Revenue	$100.0K	$2.810M
YoY Change	-96.44%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.377M
YoY Change	-100.0%
Total Short-Term Liabilities	$100.6M	$68.70M
YoY Change	46.49%
LONG-TERM LIABILITIES
Long-Term Debt	$11.00M	$18.50M
YoY Change	-40.55%
Other Long-Term Liabilities	$500.0K	$22.53M
YoY Change	-97.78%
Total Long-Term Liabilities	$11.50M	$41.03M
YoY Change	-71.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$100.6M	$68.70M
Total Long-Term Liabilities	$11.50M	$41.03M
Total Liabilities	$188.2M	$406.7M
YoY Change	-53.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$652.3M	-$521.8M
YoY Change	25.01%
Common Stock	$24.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$329.4M	-$521.8M
YoY Change
Total Liabilities & Shareholders Equity	$517.7M	$219.3M
YoY Change	136.06%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$76.90M	-$191.8M
YoY Change	-59.9%	610.54%
Depreciation, Depletion And Amortization	$5.803M	$4.902M
YoY Change	18.38%	104.25%
Cash From Operating Activities	-$81.49M	-$42.21M
YoY Change	93.08%	86.68%
INVESTING ACTIVITIES
Capital Expenditures	$1.378M	$2.075M
YoY Change	-33.59%	-61.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.913M	-$4.994M
YoY Change	-21.65%	-6.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00	$394.0K
YoY Change	-100.0%
Cash From Financing Activities	-$160.0K	-$2.278M
YoY Change	-92.98%	-148.88%
NET CHANGE
Cash From Operating Activities	-$81.49M	-$42.21M
Cash From Investing Activities	-$3.913M	-$4.994M
Cash From Financing Activities	-$160.0K	-$2.278M
Net Change In Cash	-$85.57M	-$49.48M
YoY Change	72.93%	112.63%
FREE CASH FLOW
Cash From Operating Activities	-$81.49M	-$42.21M
Capital Expenditures	$1.378M	$2.075M
Free Cash Flow	-$82.87M	-$44.28M
YoY Change	87.14%	58.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001818331
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39482
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Sema4 Holdings Corp.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1966622
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	380000000	shares
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Ludlow Street
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	North Tower, 8th Floor
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
CY2022Q1	dei	City Area Code CityAreaCode	800
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	298-6470
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	377249186	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	315002000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37642000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26509000	USD
CY2022Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	125000	USD
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	54000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	36318000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	33456000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	17241000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19154000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4096000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3802000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	410424000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	483544000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38417000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	60976000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	USD
CY2021Q4	us-gaap	Assets Assets	554093000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	68880000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6953000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6930000	USD
CY2022Q1	us-gaap	Assets Assets	517670000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	64801000	USD
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3237000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2623000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	66000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	473000	USD
CY2022Q1	cmlf	Lease Liabilities Current LeaseLiabilitiesCurrent	5072000	USD
CY2021Q4	cmlf	Lease Liabilities Current LeaseLiabilitiesCurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	23384000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33387000	USD
CY2021Q4	cmlf	Warrant Liability WarrantLiability	21555000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3432000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	100639000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101284000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2022Q1	cmlf	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	57478000	USD
CY2021Q4	cmlf	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	500000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21907000	USD
CY2022Q1	cmlf	Warrant Liability WarrantLiability	15177000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10244000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	188226000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	165990000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	380000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	245154475	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	245154475	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	963520000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-652337000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	242647604	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	242647604	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	981757000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575441000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	329444000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	517670000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	554093000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53941000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64201000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48316000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	68524000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	5625000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	-4323000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21315000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53133000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	29547000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	35366000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42784000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	102038000	USD
CY2022Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1284000	USD
CY2021Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1797000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-89305000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-196657000	USD
CY2022Q1	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	13190000	USD
CY2021Q1	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	0	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	808000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	723000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5584000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12409000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4882000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76896000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-191775000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76896000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-191775000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-191775000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	678000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17559000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	329444000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-330051000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-191775000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-521826000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-191775000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5803000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4902000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	17559000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	164962000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13190000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	43000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	1821000	USD
CY2022Q1	cmlf	Noncash Lease Expense NoncashLeaseExpense	167000	USD
CY2021Q1	cmlf	Noncash Lease Expense NoncashLeaseExpense	191000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	128000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11132000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1296000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2904000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9828000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1596000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6327000	USD
CY2022Q1	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	543000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4994000	USD
CY2022Q1	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	USD
CY2021Q1	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	-688000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	151000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3932000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3951000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-408000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1027000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-6584000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-9148000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81494000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42208000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1378000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2075000	USD
CY2022Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	2535000	USD
CY2021Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	2919000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3913000	USD
CY2022Q1	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	500000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	422000	USD
CY2021Q1	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	1254000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	862000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1052000	USD
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	394000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	702000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-160000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2278000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85567000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49480000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118960000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315902000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69480000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	607000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	723000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	168000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1325000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1164000	USD
CY2022Q1	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	717000	USD
CY2021Q1	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1570000	USD
CY2022Q1	cmlf	Deferred Transaction Costs Incurred But Not Yet Paid DeferredTransactionCostsIncurredButNotYetPaid	227000	USD
CY2021Q1	cmlf	Deferred Transaction Costs Incurred But Not Yet Paid DeferredTransactionCostsIncurredButNotYetPaid	4228000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sema4 Holdings Corp. (“Sema4 Holdings”) through its subsidiary Sema4 OpCo, Inc.,, formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”), as discussed further below, provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. Legacy Sema4 primarily serves healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Prior Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. (“Prior Merger Sub”) merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Prior Merger” and, together with the other transactions contemplated by the Prior Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Prior Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Prior Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Prior Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock (the “Class A common stock”)) (the “Conversion Ratio”).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Prior Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. See Note 3, “Business Combination,” for additional details.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiaries following the consummation of the Business Combination.</span></div>
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liability and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.</span></div>
CY2020	cmlf	Proceeds From Government Assistance ProceedsFromGovernmentAssistance	5400000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	3800000	USD
CY2021Q4	cmlf	Payment Of Deferred Payroll Taxes PaymentOfDeferredPayrollTaxes	1900000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	500000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	315002000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315902000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21995000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21994972	shares
CY2021Q4	cmlf	Warrants To Purchase Public Warrants WarrantsToPurchasePublicWarrants	14758305	shares
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q1	cmlf	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	18.00
CY2022Q1	cmlf	Redemption Price Per Warrant RedemptionPricePerWarrant	0.01
CY2022Q1	cmlf	Number Of Days For Written Notice Of Redemption NumberOfDaysForWrittenNoticeOfRedemption	30	D
CY2022Q1	cmlf	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	D
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	2700000	USD
CY2022Q1	cmlf	Contract With Customer Liability Prepayments ContractWithCustomerLiabilityPrepayments	350000	USD
CY2022Q1	cmlf	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	304000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53941000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64201000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3600000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	10300000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3296000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3769000	USD
CY2022Q1	cmlf	Contract With Customer Asset Additions ContractWithCustomerAssetAdditions	453000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3749000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3815000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	100000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	USD
CY2021Q1	cmlf	Revenue Recognized Included Contract Liability RevenueRecognizedIncludedContractLiability	500000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1500000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1800000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	300000	USD
CY2021Q1	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	300000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	315000000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	118685000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	114625000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	57709000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51906000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	60976000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5800000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4900000	USD
CY2022Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1600000	USD
CY2021Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1200000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5803000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4902000	USD
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0400
CY2022Q1	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	875000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2131000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2174000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2218000	USD
CY2022Q1	cmlf	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	3602000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	11000000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	900000	USD
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	900000	USD
CY2022Q1	cmlf	Lessee Finance Lease Interest Rate LesseeFinanceLeaseInterestRate	0.131
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38417000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	13190000	USD
CY2022Q1	cmlf	Lease Assets LeaseAssets	51607000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39649000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	17829000	USD
CY2022Q1	cmlf	Lease Liabilities LeaseLiabilities	63420000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1380000	USD
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	169000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	127000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1676000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	912000	USD
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	552000	USD
CY2022Q1	cmlf	Finance Lease Costs FinanceLeaseCosts	1464000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	3140000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3862000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	3808000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Remainder Of Fiscal Year LesseeOperatingAndFinanceAndLiabilityToBePaidRemainderOfFiscalYear	7670000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4338000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3584000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Year One LesseeOperatingAndFinanceAndLiabilityToBePaidYearOne	7922000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4440000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2763000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Two LesseeOperatingAndFinanceAndLiabilityToBePaidYearTwo	7203000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4835000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2451000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Three LesseeOperatingAndFinanceAndLiabilityToBePaidYearThree	7286000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4949000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2003000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Four LesseeOperatingAndFinanceAndLiabilityToBePaidYearFour	6952000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	51920000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	49884000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid Year Five LesseeOperatingAndFinanceAndLiabilityToBePaidYearFive	101804000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	74344000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	64493000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability To Be Paid LesseeOperatingAndFinanceAndLiabilityToBePaid	138837000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32237000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	43180000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability Undiscounted Excess Amount LesseeOperatingAndFinanceAndLiabilityUndiscountedExcessAmount	75417000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	42107000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	21313000	USD
CY2022Q1	cmlf	Lessee Operating And Finance And Liability LesseeOperatingAndFinanceAndLiability	63420000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y6M
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y9M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.105
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1236000	USD
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	552000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	862000	USD
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	19400000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22100000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	2700000	USD
CY2022Q1	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	employee
CY2022Q1	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	consultant
CY2022Q1	cmlf	Share Based Payment Arrangement Expense Reversal ShareBasedPaymentArrangementExpenseReversal	5200000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17559000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164962000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-191775000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	244368743	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	244368743	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	549778	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	549778	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-348.82
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-348.82
CY2022Q1	cmlf	Conversion Ratio ConversionRatio	123.8339
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82028603	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	201143931	shares

Files In Submission

Name	View Source	Status
0001818331-22-000046-index-headers.html	Edgar Link	pending
0001818331-22-000046-index.html	Edgar Link	pending
0001818331-22-000046.txt	Edgar Link	pending
0001818331-22-000046-xbrl.zip	Edgar Link	pending
ceocertificationfor-ex311x.htm	Edgar Link	pending
ceocertificationfor-ex321x.htm	Edgar Link	pending
cfocertificationfor-ex312x.htm	Edgar Link	pending
cfocertificationfor-ex322x.htm	Edgar Link	pending
cmlf-20220331.htm	Edgar Link	pending
cmlf-20220331.xsd	Edgar Link	pending
cmlf-20220331_cal.xml	Edgar Link	unprocessable
cmlf-20220331_def.xml	Edgar Link	unprocessable
cmlf-20220331_g1.jpg	Edgar Link	pending
cmlf-20220331_htm.xml	Edgar Link	completed
cmlf-20220331_lab.xml	Edgar Link	unprocessable
cmlf-20220331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WGS
GeneDx Holdings Corp. Stock $wgs

2022 Q1 Form 10-Q Financial Statement

#000181833122000046 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS GeneDx Holdings Corp. Stock $wgs

2022 Q1 Form 10-Q Financial Statement

#000181833122000046 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS
GeneDx Holdings Corp. Stock $wgs